Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› New Mexico
Clinical trial register · United States · industry-sponsored

Clinical Trials in New Mexico, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 10 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 5299 Florida 4438 Illinois 2485 Georgia 2364 Arizona 2242
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca6 Zimmer Biomet4 GlaxoSmithKline4 Pfizer4 N-Power Medicine3
State
California5299 Florida4438 Illinois2485 Georgia2364 Arizona2242
All 51 states
Target enrolment
to

Trials with a site in New Mexico

96 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
Microbio Co Ltd
Observational
1,500
Indiana, Maryland, New Mexico, Tennessee, Texas
2026-11
Not yet open
Boehringer Ingelheim
Phase 3
600
Arizona, California, Florida, Kansas, New Mexico, North Carolina
2026-10-23
Recruiting
Hoffmann-La Roche
Phase 3
400
California, Georgia, Michigan, Nevada, New Mexico
2026-09-30
Recruiting
Pfizer
Phase 2
120
Alabama, California, Georgia, Illinois, Nebraska, New Mexico, Tennessee
2026-06-30
Recruiting
Eikon Therapeutics
Phase 2/3
750
Alabama, California, Colorado, Florida, Illinois, New Mexico, New York, Tennessee
2026-06-15
Recruiting
GlaxoSmithKline
Phase 2
200
California, Connecticut, Florida, Georgia, Louisiana, Maryland, Missouri, New Mexico
2026-04-15
Recruiting
Kyntra Bio
Phase 2
75
Arizona, California, Connecticut, Florida, Georgia, Louisiana, New Mexico, North Carolina
2026-02-22
Recruiting
Janssen Research & Development, LLC
Phase 2
240
Arkansas, California, Florida, Georgia, Illinois, Indiana, New Mexico, North Carolina
2026-01-15
Recruiting
An External Control Arm Study in Non-Small Cell Lung Cancer
NCT07174388Non Small Cell Lung Cancer
N-Power Medicine
Observational
650
California, Delaware, Illinois, New Mexico, New York, Pennsylvania, Texas
2026-01-07
Recruiting
Xerient Pharma
Phase 1/2
36
California, Michigan, New Mexico, Texas
2026-01-01
Active, closed
Novita Pharmaceuticals, Inc.
Phase 2/3
380
Arizona, Louisiana, New Mexico, Pennsylvania, Utah, Wisconsin
2025-12-29
Recruiting
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
NCT07333183Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases
DrugMosliciguat
Pulmovant, Inc.
Phase 2
20
California, Florida, Illinois, Kansas, Massachusetts, Michigan, New Mexico, North Carolina
2025-12-23
Recruiting
Angitia Incorporated Limited
Phase 2
80
Arizona, Connecticut, Delaware, Indiana, Missouri, New Mexico, Ohio, Oregon
2025-12-12
Recruiting
UCB Biopharma SRL
Phase 1
392
Arizona, California, Colorado, Florida, Illinois, Michigan, New Jersey, New Mexico
2025-12-10
Recruiting
Ventus Therapeutics U.S., Inc.
Phase 2
24
California, Florida, Indiana, Michigan, Missouri, New Mexico, New York, Tennessee
2025-12-03
Recruiting
SAb Biotherapeutics, Inc.
Phase 2
159
California, Colorado, Florida, Georgia, Indiana, Massachusetts, Missouri, New Mexico
2025-11-25
Recruiting
DESTINY-PANTUMOUR04
NCT07124000Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer, Cervical Cancer
DrugTrastuzumab deruxtecan
AstraZeneca
Observational
100
Alabama, Arizona, California, Colorado, Florida, Illinois, Kansas, New Mexico
2025-09-18
Recruiting
Abbott Point of Care
Not applicable
425
New Mexico, Pennsylvania, Wisconsin
2025-09-17
Recruiting
Abbott Point of Care
Not applicable
425
New Mexico, Pennsylvania, Wisconsin
2025-09-17
Recruiting
Pfizer
Phase 3
140
California, Florida, Indiana, Maryland, Michigan, Nebraska, New Mexico, New York
2025-09-10
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
DrugsPRL-02·Abiraterone acetate·Prednisolone·Prednisone
Astellas Pharma Global Development, Inc.
Phase 2
218
Alabama, California, Florida, Illinois, Louisiana, New Mexico, Ohio, South Carolina
2025-08-19
Recruiting
Neurocrine Biosciences
Phase 3
550
California, Connecticut, Florida, Iowa, Louisiana, Missouri, New Mexico, New York
2025-08-18
Recruiting
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
NCT06624644Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma, Unresectable Melanoma
DrugsTemozolomide·Pembrolizumab
Linnaeus Therapeutics, Inc.
Phase 2/3
135
California, Colorado, Florida, Massachusetts, New Mexico, Pennsylvania
2025-08-06
Recruiting
Abiomed Inc.
Observational
350
Arkansas, California, Florida, Hawaii, Illinois, Massachusetts, Michigan, New Mexico
2025-07-10
Recruiting
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
NCT06933472Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Alebund Pharmaceuticals
Phase 3
264
California, Colorado, Connecticut, Florida, Georgia, Louisiana, Mississippi, New Mexico
2025-06-13
Recruiting
N-Power Medicine
Observational
130
California, Delaware, Idaho, Illinois, New Mexico, Pennsylvania, Texas
2025-06-05
Active, closed
Merck Sharp & Dohme LLC
Phase 2
130
Colorado, Kansas, New Mexico
2025-05-12
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2
83
California, Florida, Illinois, Louisiana, Massachusetts, New Mexico, New York, North Carolina
2025-04-23
Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT06906341Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
DrugsNab-paclitaxel /m^2·Relacorilant·Bevacizumab
Corcept Therapeutics
Phase 2
270
Alabama, California, Florida, Minnesota, Missouri, New Mexico, Ohio, Oregon
2025-04-11
Recruiting
Coherus Oncology, Inc.
Phase 1
154
Arizona, California, Colorado, Georgia, Louisiana, Michigan, Nevada, New Mexico
2025-04-01
Active, closed
Immutep S.A.S.
Phase 3
756
Kentucky, New Mexico, Texas
2025-03-21
Active, closed
Hoffmann-La Roche
Phase 4
274
California, Florida, Illinois, Massachusetts, Nevada, New Jersey, New Mexico, Tennessee
2025-03-14
Recruiting
Bristol-Myers Squibb
Phase 3
530
Alabama, Arkansas, Florida, Georgia, Illinois, Minnesota, New Mexico, North Carolina
2025-02-25
Recruiting
Janssen Research & Development, LLC
Phase 3
750
Arizona, Arkansas, Florida, Illinois, Maryland, Massachusetts, Minnesota, New Mexico
2025-01-09
Recruiting
A Study of RSLV-132 in Females With Sjögren's Disease
NCT06440525Primary Sjögren Syndrome
Resolve Therapeutics
Phase 2
106
California, Florida, Illinois, Iowa, Massachusetts, New Mexico, North Carolina, Pennsylvania
2024-12-01
Active, closed
Angitia Biopharmaceuticals
Phase 2
379
Alabama, Georgia, New Mexico, Pennsylvania, Washington
2024-10-31
Active, closed
BioPorto Diagnostics
Observational
800
Alabama, California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, New Mexico
2024-10-28
Recruiting
Pfizer
Phase 3
900
Arizona, Arkansas, California, Illinois, Nebraska, New Mexico, New York, South Carolina
2024-10-22
Not yet open
Abbott Nutrition
Not applicable
321
Arizona, Arkansas, Connecticut, Florida, Massachusetts, Missouri, New Mexico, New York
2024-09
Active, closed
Klein Buendel, Inc.
Not applicable
1,796
Arizona, Colorado, New Mexico, Utah
2024-08-26
Recruiting
Talphera, Inc
Not applicable
70
California, Florida, Michigan, New Mexico, New York, Ohio, Pennsylvania, South Carolina
2024-08-15
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
252
Colorado, Connecticut, Florida, Kentucky, Missouri, Nevada, New Mexico, Oklahoma
2024-06-04
Active, closed
SHINKEI Therapeutics, Inc
Phase 2
45
California, Florida, Maine, Michigan, Missouri, New Jersey, New Mexico, North Carolina
2024-06-01
Recruiting
BostonGene and Exigent Genomic INsight Study
NCT06272864Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma
BostonGene
Observational
400
Arkansas, California, Indiana, New Mexico, Oklahoma, Texas, Washington
2024-04-08
By invitation
Rekovar Inc.
Observational
100
New Mexico
2024-03-18
Active, closed
Fusion Pharmaceuticals Inc.
Phase 2
110
California, Florida, Iowa, Maryland, Michigan, Missouri, Nebraska, New Mexico
2024-03-05
Active, closed
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
NCT05458674Breast Cancer, Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer
DrugsTucatinib·Herceptin·Eribulin·Trastuzumab
Criterium, Inc.
Phase 2
17
Colorado, District of Columbia, New Mexico, Washington, Wisconsin
2024-01-30
Active, closed
Pfizer
Phase 3
394
California, Florida, Indiana, Louisiana, Maryland, Michigan, New Mexico, New York
2024-01-19
Active, closed
Kyowa Kirin Co., Ltd.
Phase 2
150
Arizona, California, Colorado, Florida, Maryland, Nevada, New Jersey, New Mexico
2024-01-09
Recruiting
Amgen
Phase 3
750
California, Delaware, Florida, Illinois, Kentucky, Massachusetts, New Mexico, New York
2023-11-16
Recruiting
Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.
NCT06157177Sciatica Acute, Lumbar Spinal Stenosis
DrugMetaxalone
Primus Pharmaceuticals
Phase 4
50
Alabama, California, Florida, Georgia, Michigan, New Mexico, North Carolina, Ohio
2023-11-15
Active, closed
Bristol-Myers Squibb
Phase 2
100
Alaska, Arizona, California, Georgia, Kentucky, New Mexico, Washington
2023-11-06
Active, closed
Nerve Protection Evaluation: Revision Cubital Tunnel Syndrome Decompression
NCT06117501Recurrent Cubital Tunnel Syndrome, Recalcitrant Cubital Tunnel Syndrome
Axogen Corporation
Not applicable
20
Florida, Georgia, Indiana, New Mexico, Ohio, Pennsylvania, Utah
2023-10-19
Recruiting
Novartis Pharmaceuticals
Phase 3
106
California, Colorado, Florida, Georgia, Massachusetts, Minnesota, Missouri, New Mexico
2023-10-02
Active, closed
AnaptysBio, Inc.
Phase 2
420
Arizona, California, Florida, Illinois, Louisiana, Massachusetts, New Mexico, North Carolina
2023-08-31
Active, closed
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)
NCT05787821Knee Pain Chronic, Osteoarthritis, Knee, Rheumatoid Arthritis, Traumatic Arthritis
Zimmer Biomet
Observational
760
Colorado, Florida, Georgia, Kentucky, Michigan, Minnesota, Mississippi, New Mexico
2023-06-28
Active, closed
Alumis Inc
Phase 2
408
Alabama, California, Florida, Georgia, Missouri, Nevada, New Jersey, New Mexico
2023-06-26
Active, closed
Gilead Sciences
Phase 2
83
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Missouri, New Mexico
2023-05-15
Active, closed
Regeneron Pharmaceuticals
Phase 2
51
California, Kentucky, New Mexico, New York, North Carolina, Texas, Virginia, Washington
2023-04-21
Active, closed
GlaxoSmithKline
Phase 2
154
California, New Mexico, New York, Pennsylvania, Tennessee, Texas, Virginia
2023-04-03
Active, closed
Assessment of GORE® SYNECOR Biomaterial in Focused Patient Populations and Long-Term Application
NCT05094089Hernia, Ventral, Hernia Incisional, Hernia Incisional Ventral
W.L.Gore & Associates
Observational
320
Georgia, Massachusetts, Michigan, New Mexico, New York, North Carolina, South Carolina, Virginia
2023-02-24
Active, closed
GlaxoSmithKline
Phase 2
351
Florida, New Mexico, Tennessee, West Virginia
2022-10-14
Recruiting
Stalicla SA
Observational
1,500
Arizona, California, Florida, Illinois, Missouri, New Mexico, Texas, Utah
2022-10-13
Active, closed
Alpha Tau Medical LTD.
Not applicable
86
Arizona, California, Florida, Georgia, Minnesota, New Jersey, New Mexico, New York
2022-09-21
Recruiting
AstraZeneca
Phase 2
454
California, Indiana, Kansas, Massachusetts, Michigan, New Jersey, New Mexico, New York
2022-09-06
Active, closed
Novartis Pharmaceuticals
Phase 3
506
California, Florida, Georgia, Illinois, Kansas, Massachusetts, New Mexico, New York
2022-08-04
Recruiting
N-Power Medicine
Observational
20,000
California, Delaware, Illinois, New Mexico, Pennsylvania, Texas
2022-08-01
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
312
California, Colorado, District of Columbia, Massachusetts, Michigan, Missouri, New Mexico, New York
2022-05-25
Active, closed
AstraZeneca
Phase 3
760
Alabama, Arizona, California, Georgia, Maryland, New Mexico, New York, Tennessee
2022-03-28
Active, closed
Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System
NCT04770870Osteoarthritis Ankle, Post-Traumatic Osteoarthritis of Ankle, Osteoarthritis of Ankle Secondary to Inflammatory Arthritis (Disorder)
DT MedTech, LLC
Not applicable
94
Arkansas, California, Florida, Indiana, Maryland, New Mexico, North Carolina, Oklahoma
2022-02-01
By invitation
AbbVie
Phase 2
116
Arizona, California, Georgia, Maryland, Massachusetts, Minnesota, Nevada, New Mexico
2021-12-20
Recruiting
Johnson & Johnson Enterprise Innovation Inc.
Phase 3
500
Alabama, California, District of Columbia, Florida, Georgia, Kentucky, Massachusetts, New Mexico
2021-12-10
Active, closed
Sanofi
Phase 2
109
Alabama, Arizona, California, Florida, New Mexico, New York, Oklahoma, Tennessee
2021-11-10
Recruiting
AstraZeneca
Phase 1/2
460
California, Louisiana, Maryland, Massachusetts, Missouri, New Mexico, New York, North Carolina
2021-10-18
Active, closed
GlaxoSmithKline
Phase 3
40
California, Colorado, Illinois, Michigan, New Mexico, New York, North Dakota, Pennsylvania
2021-06-28
Recruiting
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 2
102
California, Florida, Georgia, Indiana, Louisiana, Nebraska, New Mexico, North Carolina
2021-06-18
Active, closed
Persona Ti-Nidium Post-Market Clinical Follow-up
NCT04817969Knee Pain Chronic, Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis
Zimmer Biomet
Not applicable
240
Colorado, Maryland, Mississippi, New Mexico, North Carolina, Pennsylvania, South Dakota
2021-06-01
Recruiting
Janssen Research & Development, LLC
Phase 1/2
420
California, Illinois, Indiana, Kentucky, Massachusetts, Michigan, New Mexico, New York
2021-05-19
Active, closed
Criterium, Inc.
Phase 2
70
Arizona, California, Colorado, Connecticut, Georgia, Louisiana, Nebraska, New Mexico
2021-02-09
Active, closed
BioNTech SE
Phase 2/3
358
California, Connecticut, District of Columbia, Florida, Georgia, Kentucky, Massachusetts, New Mexico
2021-01-07
Active, closed
Daiichi Sankyo
Phase 1
145
Arizona, California, District of Columbia, Florida, Maryland, Minnesota, New Mexico, Texas
2020-09-15
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
40
Arizona, Colorado, District of Columbia, Missouri, New Mexico, North Carolina, Ohio, Washington
2020-09-15
Active, closed
AbbVie
Phase 2
146
Arizona, California, Georgia, Illinois, Maryland, Massachusetts, Nevada, New Mexico
2020-08-25
Active, closed
AstraZeneca
Phase 3
140
Colorado, Michigan, Minnesota, New Mexico, New York, Pennsylvania, Texas, Washington
2019-10-29
Active, closed
Linnaeus Therapeutics, Inc.
Phase 1/2
200
California, Connecticut, Massachusetts, New Mexico, New York, Pennsylvania, Texas
2019-10-21
Recruiting
Oxford BioTherapeutics Ltd
Phase 1
200
Arizona, California, Florida, Iowa, Kentucky, Mississippi, New Mexico, New York
2019-07-25
Active, closed
Cook MyoSite
Phase 3
96
Arizona, California, District of Columbia, Kansas, Michigan, New Mexico, New York, North Carolina
2019-04-23
Recruiting
Allarity Therapeutics
Observational
60
Florida, Georgia, New Mexico, New York, Oklahoma, Texas, Washington
2019-04-11
Active, closed
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
NCT03589339Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour, Metastasis From Malignant Tumor of Liver
DrugsJNJ-90301900·Opdivo·Nivolumab·Keytruda
Nanobiotix
Phase 1
145
California, Florida, Georgia, Illinois, Maryland, Michigan, New Mexico, New York
2019-01-16
Active, closed
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase 2
184
Arizona, California, Florida, Georgia, Kentucky, Louisiana, Minnesota, New Mexico
2018-12-21
Active, closed
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
NCT03653507Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
507
California, Kansas, Louisiana, New Mexico, New York, South Carolina, Texas, Utah
2018-11-28
Recruiting
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
NCT03556228Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer
VM Oncology, LLC
Phase 1/2
242
California, Connecticut, District of Columbia, Florida, New Jersey, New Mexico, New York, Ohio
2018-06-08
Recruiting
bioAffinity Technologies Inc.
Observational
500
New Jersey, New Mexico, Texas
2018-03-01
Active, closed
Prospective G7 Dual Mobility Total Hip PMCF
NCT03308929Clinical Outcomes, Functional Outcomes, Radiological Outcomes, Survivorship
Zimmer Biomet
Observational
250
New Jersey, New Mexico, North Carolina, Oregon, Virginia
2017-02-28
Active, closed
Persona Partial Knee Clinical Outcomes Study
NCT03034811Osteoarthritis, Avascular Necrosis, Traumatic Arthritis, Conditional Tibial Condyle or Plateau Fractures
Zimmer Biomet
Not applicable
757
California, Colorado, Illinois, Indiana, Massachusetts, Michigan, New Mexico, South Carolina
2017-02-08
Active, closed
AstraZeneca
Phase 3
953
California, Kentucky, New Jersey, New Mexico, New York, Ohio, Pennsylvania, Texas
2015-11-03
Rows per page Showing 1–96 of 96
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-usa/state/new-mexico

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 10 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 96 of those studies with a site in New Mexico.

How many clinical trials are recruiting in New Mexico?

47 of the 96 studies on this page are recruiting new participants as of the 10 Oct 2026, 03:16 UTC sync. A further 3 have not yet opened recruitment, 44 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (New Mexico), 96 studies
PhaseStudiesRecruitingShare
Phase 2331334.4%
Phase 3201020.8%
Observational15915.6%
Not applicable10310.4%
Phase 1/2767.3%
Phase 1535.2%
Phase 2/3424.2%
Phase 4212.1%

Most active sponsors

Lead sponsors with the most studies (New Mexico)
Lead sponsorStudiesRecruiting
AstraZeneca63
GlaxoSmithKline41
Pfizer43
Zimmer Biomet40
Janssen Research & Development, LLC33
N-Power Medicine33
Abbott Point of Care22
AbbVie20
Astellas Pharma Global Development, Inc.21
Bristol-Myers Squibb21
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.